Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (263)
  2. Journal Article (246)
  3. Review (27)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (576)
  2. Gastrointestinal Oncology Service (576)
  3. Solid Tumor Oncology Division (576)
  4. Center for Pancreatic Cancer Research (216)
  5. Epidemiology and Biostatistics (123)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (157)
  2. James Harding (131)
  3. Marinela Capanu (66)
  4. William Jarnagin (66)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (21)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (167)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (183)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (576)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Body mass index and somatic variants in biliary tract cancers
    Meeting Abstract

    Al Mahmasani, L.; Chou, J. F.; Capanu, M.; Srivastava, A.; Sigel, C. S.; Alsuwailem, R.; Berger, M. F.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase 3 randomized clinical trial
    Journal Article

    Lau, G.; Sangro, B.; Cheng, A. L.; Kudo, M.; Kelley, R. K.; Tak, W. Y.; Gasbarrini, A.; Reig, M.; Lim, H. Y.; Tougeron, D.; more...
    Hepatology (2025)

    Fulltext@MSK | Save
  • Immune-related adverse events are associated with improved outcomes after immune checkpoint inhibitor treatment in hepatocellular carcinoma: A systematic review and meta-analysis
    Review

    Hwang, S. Y.; Rezaee-Zavareh, M. S.; Attia, A. M.; Kaymen, E. A.; Tran, N.; Abou-Alfa, G. K.; Parikh, N. D.; Singal, A. G.; Yang, J. D.
    American Journal of Gastroenterology (2025)

    Fulltext@MSK | Save
  • The Lancet Commission on addressing the global hepatocellular carcinoma burden: Comprehensive strategies from prevention to treatment
    Review

    Chan, S. L.; Sun, H. C.; Xu, Y.; Zeng, H.; El-Serag, H. B.; Lee, J. M.; Schwartz, M. E.; Finn, R. S.; Seong, J.; Wang, X. W.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
    Journal Article

    Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Kudo, M.; Reig, M.; Breder, V.; Ryu, M. H.; Ostapenko, Y.; Sukeepaisarnjaroen, W.; more...
    Journal of Hepatology (2025)

    Fulltext@MSK | Save
  • Quantitative benefit—Risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma
    Journal Article

    Valle, J. W.; Abou-Alfa, G. K.; Kelley, R. K.; Lowery, M. A.; Shroff, R. T.; Bian, Y.; Saint-Hilary, G.; Liu, H.; Teng, Z.; Hua, Z.; more...
    ESMO Gastrointestinal Oncology (2025)

    Fulltext@MSK | Save
  • International fibrolamellar cancer registry: Opportunities and challenges
    Journal Article

    Al Mahmasani, L.; Capanu, M.; Losert, K.; Chou, J. F.; Lowery, M. A.; Hennessy, M.; Ray, M.; Chambers, S.; Yaqubie, A.; Zarski, A.; more...
    JCO Global Oncology (2025)

    Fulltext@MSK | Save
  • Neoadjuvant treatment for incidental gallbladder cancer: A systematic review
    Review

    Varshney, P.; Baghmar, S.; Sirohi, B.; Abou-Alfa, G. K.; Cao, H. T.; Sharma, L. M.; Javle, M.; Goetze, T.; Kapoor, V. K.
    Annals of Hepato-Biliary-Pancreatic Surgery (2025)

    Fulltext@MSK | Save
  • Reply to: “STRIDE's efficacy and safety in Asian hepatocellular carcinoma”
    Correspondence

    Lau, G.; Abou-Alfa, G. K.; Chan, S. L.
    Journal of Hepatology (2025)

    Fulltext@MSK | Save
  • Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma
    Journal Article

    Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
    Liver Cancer (2025)

    Fulltext@MSK | Save